Open label, efficacy and safety study of long-term 6-methylsulfinylhexyl Isothiocyanate(6-MSITC) administration to Duchenne muscular dystrophy
Phase 1
Completed
- Conditions
- Duchenne muscular dystrophy
- Registration Number
- JPRN-UMIN000033016
- Lead Sponsor
- Kobe University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Male
- Target Recruitment
- 3
Inclusion Criteria
Not provided
Exclusion Criteria
DMD patient who has a severe complication DMD patient who joined other clinical trials within 6 months DMD patient who cannot swallow a capsule
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method rinary titin concentration
- Secondary Outcome Measures
Name Time Method Serum CK level, Urinary 8OhDG Serum AST,ALT,BUN and Cr WBC,Hb,Plt Urinary NAG, Urinary beta2MG and Urinary Protein to Cr ratio.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does 6-MSITC target in Duchenne muscular dystrophy pathogenesis?
How does 6-MSITC compare to corticosteroids in DMD treatment efficacy and safety profiles?
Are there specific biomarkers that correlate with 6-MSITC response in dystrophin-deficient muscle cells?
What are the potential adverse events associated with long-term 6-MSITC administration in DMD patients?
What other isothiocyanate compounds show promise for DMD treatment in preclinical or clinical studies?